犬类疫苗市场机会、成长要素、产业趋势分析及2026-2035年预测。

预计到 2025 年，全球犬用疫苗市场价值将达到 25 亿美元，并有望以 7.3% 的复合年增长率成长，到 2035 年达到 52 亿美元。

宠物健康意识的提高、狂犬病、犬细小病毒和犬瘟热等犬类疾病发病率的上升以及对预防性保健日益重视，共同推动了疫苗接种的普及。随着全球宠物犬数量的增加，宠物饲主越来越重视疫苗接种计划，以保护狗狗免受危及生命的疾病。犬类疫苗是生物製药，利用模拟病原体但不会引起感染的抗原，刺激免疫系统辨识并抵抗特定病原体。政府主导的倡议，例如疫苗津贴宣传活动和公共卫生宣传项目，在提高疫苗接种率方面发挥着至关重要的作用。这些措施不仅能遏止疾病传播，还能促进宠物健康，鼓励定期接种疫苗，并强化犬隻预防保健的整体重要性。

预计到2025年，活病毒疫苗市场规模将达到11亿美元。活病毒疫苗含有减毒病原体，能够诱发强效且持久的免疫反应，而不会引起疾病。它们能高效诱导细胞免疫和体液免疫，提供多种犬类疾病的全面保护。由于接种次数少，活疫苗为兽医和宠物饲主带来了便利，因此广受欢迎，成为理想的疫苗接种选择。

到2025年，注射疫苗将占据75%的市场。注射疫苗因其可精准给药并能诱发稳定的免疫反应而广受欢迎。在专家的指导下，这些疫苗能够提供可靠的保护，并在常规兽医护理中拥有良好的临床记录。注射疫苗配方的持续创新进一步推动了其应用，并使其成为全球犬类免疫计画的基础。

到2025年，北美犬用疫苗，在医疗保健服务方面的支出也相当可观，这为定期接种疫苗提供了支持。此外，严格的免疫接种法规和完善的医疗保健网络鼓励犬饲主遵循建议的疫苗接种计划，从而有效预防狂犬病、犬瘟热和犬细小病毒等疾病。先进的医疗保健服务以及消费者日益增长的宠物健康投资意愿，进一步巩固了北美在犬用疫苗市场的主导地位。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 犬隻数量和宠物拥有率不断增加
    • 人们对预防兽医学的认识不断提高
    • 政府法规和强制接种疫苗
    • 扩大兽医保健基础设施
    • 宠物医疗保健支出增加
  • 产业潜在风险与挑战
    • 部分地区兽医费用上涨
    • 低温运输储存和配送面临的挑战
  • 市场机会
    • 多价疫苗和联合疫苗的研发
    • 扩大宠物预防保健计划
• 成长潜力分析
• 监理情势（基于初步调查）
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
  • 亚太地区
• 科技与创新趋势
  • 目前技术
  • 新兴技术（基于初步调查）
• 临床试验和研发管线分析（基于初步调查）
• 专利分析（基于初步研究）
• 各国养狗统计数据
• 未来市场趋势
• 人工智慧和生成式人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估计与预测：疫苗类型，2022-2035年

• 活病毒疫苗
• 失活
• 重组
• 其他疫苗类型

第六章 市场估计与预测：依疾病分类，2022-2035年

• 犬瘟热
• 犬传染性呼吸道疾病症候群（CIRDC）
• 犬小病毒
• 犬钩端螺旋体病
• 犬莱姆病
• 犬传染性肝炎
• 犬狂犬病
• 其他疾病类型

第七章 市场估计与预测：依给药途径划分，2022-2035年

• 鼻内
• 注射药物
• 口服

第八章 市场估算与预测：依最终用途划分，2022-2035年

• 动物医院
• 动物医院
• 研究机构

第九章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿拉伯聯合大公国

第十章：公司简介

• Bioveta
• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Biogenesis Bago
• Ceva Sante Animale
• Elanco Animal Health Incorporated
• HIPRA
• Indian Immunologicals Limited
• Merck & Co., Inc.
• NEOTECH
• Tecnovax
• Virbac
• Zendal Group
• Zoetis

The Global Dog Vaccine Market was valued at USD 2.5 billion in 2025 and is estimated to grow at a CAGR of 7.3% to reach USD 5.2 billion by 2035.

The expansion is fueled by increasing awareness of pet health, rising incidences of canine diseases such as rabies, parvovirus, and distemper, and a growing emphasis on preventive healthcare. As dog ownership rises worldwide, pet owners are prioritizing vaccination programs to protect their animals from life-threatening illnesses. Dog vaccines are biological formulations that stimulate the immune system to recognize and defend against specific pathogens, using antigens that mimic disease agents without causing infection. Government initiatives, including subsidized vaccination campaigns and public health awareness programs, play a crucial role in increasing immunization coverage. These measures not only reduce disease prevalence but also promote healthier pet populations, encouraging regular vaccination schedules and reinforcing the overall importance of canine preventive care.

The live attenuated segment generated USD 1.1 billion in 2025. Live attenuated vaccines contain weakened pathogens that trigger a strong and long-lasting immune response without causing illness. They are highly effective in inducing both cellular and humoral immunity, providing comprehensive protection against multiple canine diseases. Their requirement for fewer doses enhances convenience for veterinarians and pet owners, which contributes to their widespread adoption as the preferred vaccination option.

The injectable segment accounted for 75% share in 2025. Injectable vaccines are widely preferred due to their ability to deliver precise dosages and generate consistent immune responses. Administered under professional supervision, these vaccines provide reliable protection and have a well-established clinical record in routine veterinary practice. Continuous innovations in injectable vaccine formulations are further driving adoption, making them the cornerstone of canine immunization programs worldwide.

North America Dog Vaccine Market held a 45.7% share in 2025. High pet ownership, strong veterinary healthcare infrastructure, and widespread awareness of preventive care drive this growth. The region's large dog population and substantial spending on veterinary services support regular immunization practices. Moreover, strict vaccination regulations and comprehensive veterinary networks encourage dog owners to adhere to recommended schedules, ensuring protection against diseases like rabies, distemper, and parvovirus. Advanced healthcare services and growing consumer willingness to invest in pet wellbeing reinforce North America's leadership position in the dog vaccine market.

Key players operating in the Global Dog Vaccine Market include Bioveta, Boehringer Ingelheim International, Brilliant Bio Pharma, Biogenesis Bago, Ceva Sante Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck & Co., Inc., NEOTECH, Tecnovax, Virbac, Zendal Group, and Zoetis. Companies in the Dog Vaccine Market are implementing diverse strategies to strengthen their market presence and expand their foothold. They are investing heavily in research and development to enhance vaccine efficacy, create novel formulations, and extend protection against emerging canine diseases. Strategic collaborations with veterinary networks, animal healthcare providers, and government initiatives help increase product reach and vaccination coverage. Geographic expansion into high-demand regions ensures access to growing pet populations, while digital platforms and tele-veterinary services improve distribution and awareness. Firms also focus on sustainability by optimizing production processes and packaging solutions. Product diversification, including combination vaccines, booster programs, and temperature-stable formulations, enables companies to meet evolving customer needs, maintain competitive advantage, and reinforce brand loyalty across global markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Vaccine type trends
  • 2.2.3 Disease type trends
  • 2.2.4 Route of administration trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising dog population and pet ownership
    • 3.2.1.2 Growing awareness of preventive veterinary care
    • 3.2.1.3 Government regulations and vaccination mandates
    • 3.2.1.4 Expansion of veterinary healthcare infrastructure
    • 3.2.1.5 Increasing expenditure on pet healthcare
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of veterinary care in some regions
    • 3.2.2.2 Cold-chain storage and distribution challenges
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of multivalent and combination vaccines
    • 3.2.3.2 Expansion of preventive pet healthcare programs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technologies
  • 3.5.2 Emerging technologies (Driven by Primary Research)
• 3.6 Clinical trial/pipeline analysis (Driven by Primary Research)
• 3.7 Patent analysis (Driven by Primary Research)
• 3.8 Dog population stats, by country
• 3.9 Future market trends
• 3.10 Impact of AI and generative AI on the market
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Live attenuated
• 5.3 Inactivated
• 5.4 Recombinant
• 5.5 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Canine distemper
• 6.3 Canine infectious respiratory disease complex (CIRDC)
• 6.4 Canine parvovirus
• 6.5 Canine leptospirosis
• 6.6 Canine lyme disease
• 6.7 Infectious canine hepatitis
• 6.8 Canine rabies
• 6.9 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Intranasal
• 7.3 Injectable
• 7.4 Oral

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Bioveta
• 10.2 Boehringer Ingelheim International
• 10.3 Brilliant Bio Pharma
• 10.4 Biogenesis Bago
• 10.5 Ceva Sante Animale
• 10.6 Elanco Animal Health Incorporated
• 10.7 HIPRA
• 10.8 Indian Immunologicals Limited
• 10.9 Merck & Co., Inc.
• 10.10 NEOTECH
• 10.11 Tecnovax
• 10.12 Virbac
• 10.13 Zendal Group
• 10.14 Zoetis